{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T19:04:42Z","timestamp":1788289482938,"version":"build-2803163510"},"reference-count":28,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["RRCT"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Mitochondrial dysfunction and impaired mitophagy are integral to\nmyocyte loss and the progression of heart failure. Urolithin A (UA), a microbiota-produced\nmetabolite of ellagitannins and ellagic acid, is a known stimulator of mitophagy and\nmitochondrial biogenesis that has shown cardioprotective effects in experimental models.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>A randomized, double-blind, placebo-controlled 2\u00d72 crossover trial was conducted on\n10 patients with HF with reduced ejection fraction (HFrEF). The trial design involved two 4-\nweek intervention periods of UA (500 mg BID) and placebo, separated by a 2-week washout\nphase. The patients underwent two-dimensional echocardiogram examination as well as blood\nsampling at the beginning and end of each period.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>All patients completed the study. The results failed to reveal any significant effect of\nUA supplementation on echocardiographic measures (LVEF, LVEDD, LVESV, and TAPSE).\nPlasma concentrations of pro-BNP, glucose, and CRP (p &gt;0.05) were also not altered. Serum\nHDL-C levels were increased with UA compared with placebo (+6.46 \u00b1 2.33 mg\/dL, p =0.026),\nwhereas other lipid indices (LDL-C, triglycerides, total cholesterol, and VLDL-C) remained\nunchanged (p &gt;0.05).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>The results of the present study do not support any positive effect of UA\nsupplementation in improving echocardiographic and biochemical indices of HFrEF. Further studies\nwith higher doses of UA and longer supplementation duration are encouraged to be conducted.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0115748871279354240209101604","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T08:13:51Z","timestamp":1708589631000},"page":"221-228","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Evaluation of Urolithin A Efficacy in Heart Failure Patients with\nReduced Ejection Fraction: A Randomized, Double-blind, Crossover,\nPlacebo-controlled Clinical Trial"],"prefix":"10.2174","volume":"19","author":[{"given":"Tannaz","family":"Jamialahmadi","sequence":"first","affiliation":[{"name":"Medical Toxicology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maede","family":"Hasanpour","sequence":"additional","affiliation":[{"name":"Department of\nPharmacognosy and Medicinal Plants Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences,\nTehran, Iran"},{"name":"Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical\nSciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farveh","family":"Vakilian","sequence":"additional","affiliation":[{"name":"Atherosclerosis Prevention Research Centre, Faculty of Medicine, Mashhad University of\nMedical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E.","family":"Penson","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University,\nLiverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milad","family":"Iranshahy","sequence":"additional","affiliation":[{"name":"Department of Pharmacognosy, School of Pharmacy, Mashhad University of Medical\nSciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[{"name":"Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical\nSciences, Mashhad, Iran"},{"name":"Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","volume":"396","author":"Vos T.","year":"2020","unstructured":"Vos T.; Lim S.S.; Abbafati C.; Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet  2020,396(10258),1204-1222","journal-title":"Lancet"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1016\/j.jacc.2019.10.009","volume":"74","author":"Mensah G.A.","year":"2019","unstructured":"Mensah G.A.; Roth G.A.; Fuster V.; The global burden of cardiovascular diseases and risk factors. J Am Coll Cardiol  2019,74(20),2529-2532","journal-title":"J Am Coll Cardiol"},{"key":"ref=3","year":"2002","unstructured":"The world health report 2002: reducing risks, promoting healthy life. World Health Organization  2002","journal-title":"World Health Organization"},{"key":"ref=4","author":"Mendis S.","year":"2011","unstructured":"Mendis S.; Puska P.;  Norrving Be, Organization WH Global atlas on cardiovascular disease prevention and control  2011","journal-title":"Norrving Be, Organization WH Global atlas on cardiovascular disease prevention and control"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","volume":"385","author":"Abubakar I.","year":"2015","unstructured":"Abubakar I.; Tillmann T.; Banerjee A.; Global, regional, and national age\u2013sex specific all-cause and cause-specific mortality for 240 causes of death, 1990\u20132013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet  2015,385(9963),117-171","journal-title":"Lancet"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.carpath.2011.11.007","volume":"21","author":"Kemp C.D.","year":"2012","unstructured":"Kemp C.D.; Conte J.V.; The pathophysiology of heart failure. Cardiovasc Pathol  2012,21(5),365-371","journal-title":"Cardiovasc Pathol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/cphy.c140055","volume":"6","author":"Tanai E.","year":"2015","unstructured":"Tanai E.; Frantz S.; Pathophysiology of heart failure. Compr Physiol  2015,6(1),187-214","journal-title":"Compr Physiol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1161\/CIRCULATIONAHA.107.702795","volume":"116","author":"Ashrafian H.","year":"2007","unstructured":"Ashrafian H.; Frenneaux M.P.; Opie L.H.; Metabolic mechanisms in heart failure. Circulation  2007,116(4),434-448","journal-title":"Circulation"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1161\/CIRCRESAHA.115.305765","volume":"117","author":"Dassanayaka S.","year":"2015","unstructured":"Dassanayaka S.; Jones S.P.; Recent developments in heart failure. Circ Res  2015,117(7),e58-e63","journal-title":"Circ Res"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3390\/jcm5070062","volume":"5","author":"Inamdar A.","year":"2016","unstructured":"Inamdar A.; Inamdar A.; Heart failure: Diagnosis, management and utilization. J Clin Med  2016,5(7),62","journal-title":"J Clin Med"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"McMurray J.J.V.","year":"2014","unstructured":"McMurray J.J.V.; Packer M.; Desai A.S.; Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med  2014,371(11),993-1004","journal-title":"N Engl J Med"},{"key":"ref=12","first-page":"464","volume":"42","author":"Shah A.","year":"2017","unstructured":"Shah A.; Gandhi D.; Srivastava S.; Shah K.J.; Mansukhani R.; Heart failure: A class review of pharmacotherapy. PandT  2017,42(7),464-472","journal-title":"PandT"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00109-015-1254-6","volume":"93","author":"Shires S.E.","year":"2015","unstructured":"Shires S.E.; Gustafsson \u00c5.B.; Mitophagy and heart failure. J Mol Med  2015,93(3),253-262","journal-title":"J Mol Med"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"419","DOI":"10.14336\/AD.2019.0518","volume":"11","author":"Yang Y.","year":"2020","unstructured":"Yang Y.; Li T.; Li Z.; Liu N.; Yan Y.; Liu B.; Role of mitophagy in cardiovascular disease. Aging Dis  2020,11(2),419-437","journal-title":"Aging Dis"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/ptr.7290","volume":"36","author":"Hasheminezhad S.H.","year":"2022","unstructured":"Hasheminezhad S.H.; Boozari M.; Iranshahi M.; A mechanistic insight into the biological activities of urolithins as gut microbial metabolites of ellagitannins. Phytother Res  2022,36(1),112-146","journal-title":"Phytother Res"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s00394-003-0396-4","volume":"42","author":"Cerd\u00e1 B.","year":"2003","unstructured":"Cerd\u00e1 B.; Llorach R.; Cer\u00f3n J.J.; Esp\u00edn J.C.; Tom\u00e1s-Barber\u00e1n F.A.; Evaluation of the bioavailability and metabolism in the rat of punicalagin, an antioxidant polyphenol from pomegranate juice. Eur J Nutr  2003,42(1),18-28","journal-title":"Eur J Nutr"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s00394-004-0461-7","volume":"43","author":"Cerd\u00e1 B.","year":"2004","unstructured":"Cerd\u00e1 B.; Esp\u00edn J.C.; Parra S.; Mart\u00ednez P.; Tom\u00e1s-Barber\u00e1n F.A.; The potent in vitro antioxidant ellagitannins from pomegranate juice are metabolised into bioavailable but poor antioxidant hydroxy-6H-dibenzopyran-6-one derivatives by the colonic microflora of healthy humans. Eur J Nutr  2004,43(4),205-220","journal-title":"Eur J Nutr"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.fct.2017.07.050","volume":"108","author":"Heilman J","year":"2017","unstructured":"Heilman J; Andreux P; Tran N; Rinsch C; Blanco-Bose W.; Safety assessment of Urolithin A, a metabolite produced by the human gut microbiota upon dietary intake of plant derived ellagitannins and ellagic acid. Food Chem Toxicol  2017,108(Pt A),289-97","journal-title":"Food Chem Toxicol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s42255-019-0073-4","volume":"1","author":"Andreux P.A.","year":"2019","unstructured":"Andreux P.A.; Blanco-Bose W.; Ryu D.; The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nat Metab  2019,1(6),595-603","journal-title":"Nat Metab"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"A531","DOI":"10.1161\/res.125.suppl_1.531","volume":"125","author":"Wu X.","year":"2019","unstructured":"Wu X.; Zhu X.; Zhou Y.; Urolithin a suppress cardiac fibrosis via autophagy pathway in the diabetic cardiomyopathy. Circulat Res  2019,125(S1),A531","journal-title":"Circulat Res"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12933-017-0561-3","volume":"16","author":"Savi M.","year":"2017","unstructured":"Savi M.; Bocchi L.; Mena P.; In vivo administration of urolithin A and B prevents the occurrence of cardiac dysfunction in streptozotocin-induced diabetic rats. Cardiovasc Diabetol  2017,16(1),80","journal-title":"Cardiovasc Diabetol"},{"key":"ref=22","first-page":"1832","volume":"19","author":"Ganjali S.","year":"2023","unstructured":"Ganjali S.; Matbou Riahi M.; Mahboobnia K.; An in vitro investigation of the effects of urolithins A and B on low-density lipoprotein uptake and its regulatory genes. Arch Med Sci  2023,19(6),1832-1841","journal-title":"Arch Med Sci"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.bbrc.2017.03.119","volume":"486","author":"Tang L.","year":"2017","unstructured":"Tang L.; Mo Y.; Li Y.; Urolithin A alleviates myocardial ischemia\/reperfusion injury via PI3K\/Akt pathway. Biochem Biophys Res Commun  2017,486(3),774-780","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"293","DOI":"10.4097\/kja.21165","volume":"74","author":"Lim C.Y.","year":"2021","unstructured":"Lim C.Y.; In J.; Considerations for crossover design in clinical study. Korean J Anesthesiol  2021,74(4),293-299","journal-title":"Korean J Anesthesiol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.3390\/nu13092957","volume":"13","author":"Penson P.E.","year":"2021","unstructured":"Penson P.E.; Banach M.; Nutraceuticals for the control of dyslipidaemias in clinical practice. Nutrients  2021,13(9),2957","journal-title":"Nutrients"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"856","DOI":"10.5114\/aoms\/133716","volume":"17","author":"Banach M.","year":"2021","unstructured":"Banach M.; Katsiki N.; Latkovskis G.; Postmarketing nutrivigilance safety profile: A line of dietary food supplements containing red yeast rice for dyslipidemia. Arch Med Sci  2021,17(4),856-863","journal-title":"Arch Med Sci"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1093\/cvr\/cvy198","volume":"115","author":"Penson P.","year":"2019","unstructured":"Penson P.; Long D.L.; Howard G.; Associations between cardiovascular disease, cancer, and very low high-density lipoprotein cholesterol in the REasons for Geographical and Racial Differences in Stroke (REGARDS) study. Cardiovasc Res  2019,115(1),204-212","journal-title":"Cardiovasc Res"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1002\/jcsm.12344","volume":"9","author":"Penson P.E.","year":"2018","unstructured":"Penson P.E.; Mancini G.B.J.; Toth P.P.; Introducing the \u2018Drucebo\u2019 effect in statin therapy: A systematic review of studies comparing reported rates of statin\u2010associated muscle symptoms, under blinded and open\u2010label conditions. J Cachexia Sarcopenia Muscle  2018,9(6),1023-1033","journal-title":"J Cachexia Sarcopenia Muscle"}],"container-title":["Reviews on Recent Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115748871279354240209101604","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/227184\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115748871279354240209101604","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T06:26:45Z","timestamp":1726813605000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/227184\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115748871279354240209101604","relation":{},"ISSN":["1574-8871"],"issn-type":[{"value":"1574-8871","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-09-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}